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• Multiple Myeloma is associated with bleeding disorders in

approximately 15% of cases
• The underlying physiologic mechanisms remain incompletely
understood and create significant clinical challenges when
approaching treatment
• The development of a heparin-like anticoagulant (HLAC) in
plasma cell neoplasia has been described in literature and
may be a mechanism of action to which bleeding occurs in
2
patients with MM
• Infusions of protamine sulfate have been proposed as a
2
potential therapy in this clinical setting
1

• Labs showed prolonged partial thromboplastin time (PTT)

and thrombin time. Transfusions of platelets, blood and
fresh frozen plasma were unable to control the bleeding
• After literature review, the patient was started on
protamine sulfate infusion resulting in significant
improvement in his bleeding. The patient’s hospital course
was complicated by acute liver failure and worsening renal
failure and was transitioned to comfort measures only

Significant Laboratory Values

Case Presentation

• A 62 year-old male with a past medical history of

Monoclonal Gammopathy of Undetermined Significance
and basal cell carcinoma presented to the ED with
complaints of non-radiating epigastric abdominal pain
for one week
• On admission he was found to have hypercalcemia, renal
failure, and pancytopenia. Hematological work up revealed
significantly elevated kappa light chains consistent with
myeloma and a bone marrow biopsy revealing circulating
plasma cells
• His mental status did not improve over a 15-day hospital
course he was transferred to our facility. On presentation
the patient was not oriented to person place or time, was
writhing, moaning and completely non verbal

© 2019 Lehigh Valley Health Network

2

Department of Medicine and Division of Hematology/Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania

1

Introduction
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Discussion

• Secretion of HLAC in Plasma Cell Neoplasia has been

described in case reports but affirmative research on
the topic remains sparse
• Literature suggests that HLAC may be paraproteins
produced within myeloma while other studies have
suggested these proteins that are similar to heparin
sulfate may be responsible by binding antithrombin
2,3,4
and leading to activation of the heparin binding site
• Regardless of the mechanism, prior cases have
demonstrated that administration of 10, 50, 100, and
200 mg/mL of protamine sulfate in patients with
myeloma improved thrombin time from >600 seconds
to 187 seconds, 76 seconds, 22 seconds, and
3
21 seconds respectively
• In the present case, once the patient was started on
protamine sulfate, his bleeding significantly improved and
his PTT normalized. Once off the infusion, his PTT and
thrombin time both became elevated again
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